Common GLP-1 RA Medications The regulatory approval status of GLP-1 drugs varies across global and national health authorities
Key Takeaways: GLP-1 use among patients newly diagnosed with Polycystic Ovary Syndrome (PCOS) without type 2 diabetes rose 6.7-fold between 2020 and 2024
0.5% WL with placebo) [35], while phase 2 results for survodutide (4.8 mg weekly for 46 weeks) demonstrated an 18.7% reduction in bodyweight (vs
Opportunities for CPG Companies Not only is there an overall pursuit of healthier foods, but the appetite-suppressing effects of GLP-1 drugs are expected to result in a 2.5% decrease in food consumption in the US
This hormone activates receptors that control skin color, metabolism, and cellular signaling
2026, GLP-1 face is on every consult Ozempic, Mounjaro, and Wegovy weight loss has produced a new aesthetic concern set: hollowing in the temples, mid-face, jawline, and tear troughs at a faster rate than aging alone would produce